| |
Arthritis News Archive23-Feb-2008
Glenmark's arthritis drug enters Phase I trial (Pharmaceutical Business Review)
Glenmark Pharmaceuticals has said that its drug candidate for rheumatoid arthritis, inflammation and multiple sclerosis, GRC 4039 has entered Phase I trials.
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis (The San Francisco Examiner)
ABBOTT PARK, Ill. ( Map ) - ABBOTT PARK, Ill., Feb. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.
Abbott gets OK for Humira in children's arthritis (Crain's Chicago Business)
(AP) ? Abbott Laboratories said Friday it received U.S. approval to market its drug Humira for a new use against arthritis in children. The Food and Drug Administration approved the new use based on studies showing that children with juvenile rheumatoid arthritis had fewer symptoms while ...
(AFX UK Focus) 2008-02-22 15:18 GMT: Abbott receives FDA approval for juvenile idiopathic arthritis drug (Interactive Investor)
NEW YORK (Thomson Financial) - Abbott Friday said it had received marketing approval from the U.S. Food and Drug Administration for its Humira drug, which treats juvenile idiopathic arthritis.
Medistem and Collaborators Publish Arthritis Paper (Marketwire via Yahoo! Finance)
Medistem Laboratories, Inc. (Frankfurt: S2U) announced today the publication of a paper entitled "Antigen-specific therapy of rheumatoid arthritis" in the February issue of the peer-reviewed journal Expert Opinion on Biological Therapies. The article, which was written by scientists at Medistem, the University of Western Ontario, and the University of Toronto, describes methods of selectively ...
Back to Alternative Treatments for Arthritis
Back to Arthritis News Archive
|
|
|